article · Exploration of Immunology
Obesity is a complex inflammatory and metabolic condition defined by excess fat accumulation and chronic low-grade inflammation. Adipose tissue secretes active signalling molecules known as adipokines, among which Isthmin-1 has emerged as an important regulator of metabolism and immune responses. Widely expressed across adult tissues, Isthmin-1 correlates with central adiposity and metabolic dysfunction. It improves glucose uptake independently of insulin by activating integrin alpha-V-beta-5 and the PI3K/Akt pathway, which triggers GLUT4 translocation. It also manages lipid metabolism by curbing lipogenesis and encouraging fatty acid oxidation. Furthermore, the molecule provides anti-inflammatory actions by suppressing NF-kappa-B signalling and guiding macrophages toward an anti-inflammatory state. While physical exercise reliably improves metabolic profiles and reduces inflammation, its direct influence on Isthmin-1 remains unstudied, highlighting an opportunity to explore its utility as a therapeutic target or biomarker.
Metabolic disorders such as obesity involve impaired glucose handling, poor fat regulation, and sustained tissue inflammation. Understanding how Isthmin-1 controls these processes independently of standard insulin signalling reveals new biological pathways. Clarifying how lifestyle interventions like exercise influence this molecule could eventually guide improved strategies to prevent or manage obesity-related metabolic diseases.
The findings highlight Isthmin-1 as a potential therapeutic target or diagnostic biomarker for obesity and broader metabolic disorders. Relevant users include pharmaceutical developers and clinical researchers investigating metabolic therapeutics. However, this is early-stage research focused on biological mechanisms and literature gaps, meaning any therapeutic intervention or diagnostic tool remains distant from real-world clinical application.
AI-generated from the published abstract. Always read the original work before citing.
Obesity is a major global health challenge, now recognized as a complex metabolic and inflammatory disorder characterized by excess adiposity and chronic low-grade inflammation. Adipose tissue functions as an endocrine organ, secreting adipokines that regulate metabolism and immune responses. Among these, Isthmin-1 (ISM1) has recently emerged as a novel adipokine with important metabolic and anti-inflammatory roles. ISM1 is widely expressed in adult tissues and is associated with central adiposity and metabolic dysfunction. It enhances glucose uptake via an insulin-independent PI3K/Akt pathway through integrin αVβ5 activation, promoting GLUT4 translocation. ISM1 also regulates lipid metabolism by inhibiting lipogenesis and stimulating fatty acid oxidation. Additionally, it exerts anti-inflammatory effects by suppressing NF-κB signaling and promoting macrophage polarization toward an anti-inflammatory phenotype. Exercise is known to improve adipokine profiles, insulin sensitivity, and inflammation, but its effects on ISM1 remain unexplored. This represents a critical gap in the literature. Understanding how different exercise modalities influence ISM1 could reveal new mechanisms underlying exercise benefits and support its potential as a biomarker or therapeutic target in obesity and metabolic disorders.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.37349/ei.2026.1003263
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
